Search clinical trials for: SYN125

Total 22 results

Synermore Biologics Co., Ltd.
Synermore Biologics USA Limited

Active, not recruiting

A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions

Solid Tumor | Epithelial Carcinoma

United States
Biotie Therapies Inc.
Massachusetts General Hospital; Michael J. Fox Foundation for Parkinson's Research and other collaborators

Completed

SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE) (SYNAPSE)

Parkinson's Disease Dementia (PDD)

United States
Biotie Therapies Inc.

Completed

Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off

Parkinson's Disease

Ukraine, Argentina, Romania, Canada, United States, Chile
Biotie Therapies Inc.
Acorda Therapeutics

Terminated

Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.

Idiopathic Parkinson Disease

United States, Canada, United Kingdom
Silence Therapeutics plc

Completed

A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome

Non-transfusion-dependent Thalassemia | Low Risk Myelodysplastic Syndrome | Very-Low Risk Myelodysplastic Syndrome

Thailand, Israel, Jordan, United Kingdom, Germany, Italy, Malaysia
Silence Therapeutics plc

Completed

A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers

Healthy Volunteers

United Kingdom
Biotie Therapies Inc.

Terminated

Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients (TOZ-PD)

Idiopathic Parkinson's Disease

Germany, Spain, Canada, United States, Italy, Austria, Czechia
Biotie Therapies Inc.

Completed

Study to Evaluate SYN115 in Parkinson's Disease

Parkinson's Disease

United States
Virginia Commonwealth University
National Institute on Drug Abuse (NIDA); The University of Texas Health Science...

Completed

An fMRI Study of SYN115 in Cocaine Dependent Subjects

Cocaine Dependence

United States
Jiangsu Yahong Meditech Co., Ltd aka Asieris

Recruiting

A Phase 1b Study to Evaluate APL-1401 in Patients With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

United States
Silence Therapeutics plc

Recruiting

Study to Assess SLN124 in Patients With Polycythemia Vera (SLN)

Polycythemia Vera

United States, Australia, Malaysia, Bulgaria, Poland
Synermore Biologics Co., Ltd.
Synermore Biologics USA Limited

Completed

Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies (ARPEP)

Rabies

United States, Philippines
Michael E. DeBakey VA Medical Center
Tuscaloosa Veterans Affairs Medical Center; Acorda Therapeutics; Ralph H. Johnson...

Withdrawn

Pharmacogenetic Clinical Trial of Nepicastat for Post Traumatic Stress Disorder (PTSD)

Post Traumatic Stress Disorder (PTSD)

United States
Biotie Therapies Inc.
National Institute on Drug Abuse (NIDA)

Completed

Study of Safety and Potential Efficacy of SYN117 in Cocaine Dependent Volunteers

Cocaine Dependence

United States
Kyowa Kirin Co., Ltd.

Completed

A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma

Multiple Myeloma and Malignant Lymphoma

Japan
Synermore Biologics (Suzhou) Co., Ltd.

Completed

A Bridging Study of the SYN023 on Healthy Adult Subjects

Vaccine Reaction | Rabies Human | Immunisation Reaction | Zoonotic Disease | Communicable Disease Transmission

China
Silence Therapeutics plc

Withdrawn

Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124

Non-transfusion-dependent Thalassemia | Low Risk Myelodysplastic Syndrome

United Kingdom, Bulgaria
Biotie Therapies Inc.
Syneos Health

Completed

Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)

Generalized Anxiety Disorder

United States
Synermore Biologics Co., Ltd.
inVentiv Health Clinical

Completed

A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines (RabiesMab)

Human Rabies

United States
Tuscaloosa Research & Education Advancement Corporation
Baylor College of Medicine; James J. Peters Veterans Affairs Medical Center; Acorda... and other collaborators

Completed

Nepicastat for Posttraumatic Stress Disorder (PTSD) in OIF/OEF Veterans (Nepicastat)

Posttraumatic Stress Disorder

United States
Biotie Therapies Inc.
Acorda Therapeutics

Terminated

A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users

Abuse Potential

Canada
Synermore Biologics (Suzhou) Co., Ltd.
Simoon Record Pharma Information Consulting Co., Ltd.

Completed

A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety

RNA Virus Infections | Virus Diseases | Mononegavirales Infections | Rabies | Rhabdoviridae Infections | Communicable Disease

China

Search clinical trials for: SYN125

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations